Difference between revisions of "POEMS syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "</big>" to "") |
Warner-admin (talk | contribs) m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
| (One intermediate revision by the same user not shown) | |||
| Line 42: | Line 42: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. [https://doi.org/10.1111/bjh.14966 link to original article] ''' | + | # Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. [https://doi.org/10.1111/bjh.14966 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/29048107/ PubMed] EudraCT 2008-003202-33 |
[[Category:POEMS syndrome regimens]] | [[Category:POEMS syndrome regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Plasma cell dyscrasias]] | [[Category:Plasma cell dyscrasias]] | ||
Latest revision as of 12:24, 15 July 2024
| Section editor | |
|---|---|
 |
Samuel M. Rubinstein, MD University of North Carolina Chapel Hill, NC, USA |
POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes
1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
EMN
- 2018: Gavriatopoulou et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias PubMed
All lines of therapy
Lenalidomide & Dexamethasone (Rd)
Rd: Revlimid (Lenalidomide) & low-dose dexamethasone
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Nozza et al. 2017 | 2009-10 to 2014-10 | Phase 2, fewer than 20 pts |
Targeted therapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
Glucocorticoid therapy
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive therapy
- Aspirin 100 mg PO once per day
- LMWH in "intolerant" patients
- Cotrimoxazole 800 mg PO twice per day two days per week
28-day cycle for at least 6 cycles
References
- Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article dosing details in manuscript have been reviewed by our editors PubMed EudraCT 2008-003202-33